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Plasma membraneThe vitamin D binding protein (DBP) is a multifunctional, albumin-like plasma protein that often requires
cell surface binding to mediate some of its diverse functions. DBP binds to several different molecules on the
external face of the plasma membrane indicating that it may possess distinct cell binding sequences. In this
report, surface plasmon resonance was utilized to evaluate the relative binding of the human myeloid cell
line U937 to immobilized recombinant expressed DBP in order to identify cell localization sequences. U937
cells showed robust binding to immobilized native DBP, but essentially no interaction when sensor chips
were coated with β2-microglobulin or BSA. The cell–DBP interaction was completely eliminated if cells were
pretreated with soluble DBP. Recombinant DBP domains and truncated domains were next evaluated to
determine the location of cell binding regions. Domains I (amino acids 1–191) and III (379–458), but not
domain II (192–378), could support cell binding. Further evaluation of domain I, using truncated proteins
and overlapping peptides, demonstrated that a single amino acid sequence, residues 150–172
(NYGQAPLSLLVSYTKSYLSMVGS), mediated cell binding. The domain III cell binding region was investigated
using truncated versions of domain III fused to full-length domain II that served as a scaffold. These
experiments indicated that the cell binding sequence is located in the ﬁrst portion of that domain (379–402:
ELSSFIDKGQELCADYSENTFTEY). Overlapping peptides spanning this sequence could partially block cell
binding only when used in combination. We conclude that DBP contains two cell localization sequences that
may be required for some of the multiple functions of this protein.P, damage-associated molec-
sponse steroid receptor; RU,
5aR, U937 cell line transfected
).
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Vitamin D binding protein (DBP) is a multifunctional and highly
polymorphic plasma protein synthesized primarily in the liver [1,2].
DBP (also referred to as Gc-globulin) is a member of the albumin gene
family and has the characteristic multiple disulﬁde-bonded, triple
domain structure [1,2]. The plasma concentration of DBP is 6–7 µM
but the protein is ubiquitous in vivo and signiﬁcant quantities (0.1–
1 µM) have been detected in all ﬂuid compartments (cerebrospinal,
bronchoalveolar, synovial, etc.) [1,3]. In contrast to albumin, DBP
levels in blood rise modestly (20–50%) during the acute phase
inﬂammatory response [1,2]. DBP has several distinct and outwardly
unrelated functions including a vitamin D transport protein, an
extracellular scavenger for G-actin released from necrotic cells, a
chemotactic cofactor for the complement activation peptide C5a, and
a macrophage and osteoclast activating factor [1,2]. Ligand binding
regions within the 458 amino acid sequence of DBP have been
identiﬁed: a vitamin D sterol binding segment in the N-terminaldomain (amino acids 35 to 49) and a G-actin binding region in the C-
terminal domain (amino acids 373 to 403) [4,5]. More recent work on
the crystal structure of DBP (bound to either vitamin D3 or actin) has
conﬁrmed the vitamin D sterol binding site, but has demonstrated
that actin interacts with distinct amino acid sequences in all three DBP
domains [6–9]. These studies also revealed that DBP is a broad U-
shaped or saddle-shaped molecule with domains I and III forming the
front and back of the saddle and domain II the seat [6–9]. This shape is
designed to perfectly ﬁt a G-actin molecule. Vitamin D sterol binding
pocket is distinct in domain I and DBP can bind both ligands
independently [4]. Recently, we have identiﬁed a 20 amino acid
sequence in the N-terminal domain (amino acids 130–149) that is
essential for the protein to function as a chemotactic cofactor for C5a
[10].
All of the cellular functions of DBP require that the protein binds to
its target cell surface. Numerous investigators have reported a cell-
associated form of DBP in many cell types including all leukocytes
[11–22]. Cell-associated DBP is not a novel cellular form but rather
plasma-derived DBP bound to the cell surface [23]. DBP appears to
bind with low avidity to multiple cell surface ligands such as
chondroitin sulfate proteoglycans [24], megalin [25,26], cubulin
[26], CD44 and annexin A2 [27]. Since the interaction of DBP with
plasmamembrane ligands is central to its cell-mediated functions, the
objective of this study was to identify cell binding sequences within
DBP. Our experimental approach utilized surface plasmon resonance
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proteins and peptides. SPR is considerably more sensitive and
reproducible than previous methods we have used to study cell
binding where DBP was covalently coupled to either 125I [24] or
Alexaﬂuor-488 [27]. Although SPR usually is employed to quantitate
the interaction between two puriﬁed molecules, it also can be used to
measure the relative binding of cells (suspended in media) to an
immobilized ligand [28]. The human myeloid cell line U937 was
utilized since these cells grow in suspension and previous data has
shown that DBP binding to U937 cells essentially is identical to
neutrophils obtained from peripheral blood [29,30]. In addition, we
have recently demonstrated that neutrophil binding to immobilized
DBP using SPR [31] is almost identical to that of U937 cells reported
herein. Results show that molecules on the surface of U937 cells bind
two distinct amino acid sequences in DBP, one in the N-terminal
domain (domain I) and the other in the C-terminal domain (domain
III). Analysis of the three-dimensional structure of DBP reveals that
the location of these sequences, conceivably, could permit DBP to
function as an adaptor protein and bridge two distinct cell surface
molecules. This multi-ligand binding may be necessary for DBP to
mediate its cellular functions.
2. Materials and methods
2.1. Reagents
Human DBP was puriﬁed from plasma and obtained from Athens
Research and Technology (Athens, GA). Full-length human DBP cDNA
(Gc-2 allele, GenBank Accession Number P02774), clone number
CS0DM004YF02, was purchased from Invitrogen (Carlsbad, CA). DNA
restriction and modiﬁcation enzymes were purchased from New
England Biolabs (Beverley, MA). Oligonucleotides were synthesized
by Invitrogen. pGEX-4T-2 expression vector was purchased from
Amersham BioSciences (Piscataway, NJ). The IgG fraction of poly-
clonal goat anti-human DBP was purchased from DiaSorin, (Still-
water, MN) and then afﬁnity puriﬁed using immobilized DBP.
Protease inhibitor cocktail mixture was obtained from Sigma-Aldrich
(St. Louis, MO).
2.2. Cells and cell culture
U937 cells were originally obtained from the American Type
Culture Collection (Manassas, VA) and transfected with either the
human C5a receptor (C5aR) or the empty plasmid vector as detailed
previously [29]. U937 cells were cultured at 37 °C and 5% CO2
suspended in RPMI 1640 containing 10% FBS (HyClone, Logan, UT)
and 400 µg/ml active G418 (Invitrogen Life Technologies, Carlsbad,
CA), and maintained at a density between 2×105 and 1.5×106 per
milliliter.
2.3. Construction of recombinant expressed DBP (reDBP) domains and
DBP peptides
To construct GST fusion proteins, DNA sequences corresponding to
the indicated DBP domains were ampliﬁed by PCR, designed to
generate products with 5′ BamHI and 3′ XhoI restriction sites. The E.
coli expressed proteins were designated as follows: DBP domain I
(residues 1–191), truncated (Δ) DBP domain I (ΔDI 1–125), truncated
DBP domain I (ΔDI 1–175), DBP domain II (192–378), DBP domain III
(379–458) DBP domains II and III (192–458), DBP domain II and ΔDIII
(192–402), and DBP domain II and ΔDIII (192–430). These were
cloned into the corresponding site using pGEX-4T-2 expression
plasmid as GST fusion partners in E. coli (sequences of all primers
available from the authors upon request). E. coli strain XL-1 Blue
(Stratagene, CA) served as the host for DNA manipulation and the E.
coli strain BL-21 served as the host for protein expression. Eachconstruct was conﬁrmed by DNA sequencing. DBP-derived peptides
were synthesized and puriﬁed (N95% purity) by the American Peptide
Company, Inc. (Sunnyvale, CA). Since all 28 cysteine residues in DBP
form paired disulﬁde bonds, peptides were constructed to avoid free
cysteine residues that could result in artifactual binding to cells.
Peptides were designated as follows: domain I peptide 1 (DIp1)
residues 130–152 (EAFRKDPKEYANQFMWEYSTNYG); domain I pep-
tide 2 (DIp2) residues 150–172 (NYGQAPLSLLVSYTKSYLSMVGS);
domain III peptide 1 (DIIIp1) residues 378–390 (KELSSFIDKGQEL);
domain III peptide 2 (DIIIp2) residues 392–412 (ADYSENTFTEYKKK-
LAERLKA); domain III peptide 3 (DIIIp3) residues 402–416 (YKKK-
LAERLKAKLPD); domain III peptide 4 (DIIIp4) residues 414–434
(LPDATPKELAKLVNKRSDFAS); domain III peptide 5 (DIIIp5) residues
438–445 (SINSPPLY); and domain III peptide 6 (DIIIp6) residues 447–
458 (DSEIDAELKNIL). A complete list of truncated DBP domains and
DBP-derived peptides and their properties is listed in Table 1, the
theoretical pI and molecular mass for each sequence was calculated
using the Compute pI/MW tool available on the ExPASy website
(http://ca.expasy.org/tools/pi_tool.html).
2.4. Expression and puriﬁcation of reDBP domains
DBP domains were expressed in E. coli according to the protocol
described by Swamy et al. [32]. BL21 cells carrying pGEX-4T-2
plasmids expressed fusion protein GST linked to the DBP constructs. E.
coli were grown at room temperature (22–24 °C) in Luria Broth (LB)
containing 100 µg/ml ampicillin and 50 µg/ml chloramphenicol until
absorbance at 600 nm (Abs 600) was 0.4–0.6. The expression of fusion
proteins was induced by the addition of 0.5–1.0 mM IPTG for 4–8 h.
Cells were collected by centrifugation at 5000×g. The E. coli pellets
(from 1 l) were resuspended in 40 ml TBS (50 mM Tris–HCl, pH 8.3,
150 mMNaCl) containing 0.2 mg/ml lysozyme, 0.1% Triton X-100 and
2 ml of a protease inhibitor cocktail mixture. The cells were disrupted
by sonication and insoluble material was removed by centrifugation
at 12,000×g for 20 min. The detergent soluble cell lysate containing
the expressed fusion protein was mixed with 1 ml of 50% slurry of
glutathione–agarose, preequilibrated in TBS. After several washes
with TBS, the bound GST-DBP was eluted with 20 mM oxidized
glutathione in 100 mM Tris buffer, pH 8.3. The fusion protein
subsequently was cleaved with thrombin and dialyzed against PBS
to remove oxidized glutathione and GST was separated from reDBP
using glutathione–sepharose afﬁnity column. Sequencing ﬁdelities of
the reDBPs were conﬁrmed by N-terminal sequencing.
2.5. Surface plasmon resonance (SPR) measurement of DBP–cell binding
The interactions between cells and DBP were evaluated using a
BIAcore 2000 (BIAcore AB, Upsala, Sweden). Full-length native DBP,
individual domains or DBP peptides were covalently coupled to a CM5
sensor chip using N-ethyl-N-(dimethylaminopropyl) carbodiimide/
N-hydroxysuccinimide (EDC/NHS) according to the manufacturer's
instructions. The surface of the CM5 sensor chip was activated with
EDC/NHS for 20 min before adding either DBP (5 µM) or DBP peptides
(100 µM) in 10 mM sodium carbonate buffer, pH 5.0. Excess NHS was
deactivated for 20 min using 1 M ethanolamine, pH 8.5. The efﬁciency
of DBP coupling was determined by injecting 5 µg/ml afﬁnity-puriﬁed
goat anti-human DBP into the ﬂow cell at 10 µl/min at 22 °C. Cell–DBP
binding interactions were determined by injecting cell suspensions at
a ﬂow rate of 5 µl/min at 22 °C in Hanks' balanced salt solution, pH 7.4
(HBSS) containing 0.005% Tween 20. The sensor chip was stripped
and regenerated using 0.8 M glycine (pH 2.0) containing 0.6 M NaCl.
The regeneration conditions were adjusted to achieve a subsequent
binding response that was within 10% of the initial (ﬁrst injection)
binding value. A blank sensor chip that was EDC/NHS-activated and
ethanolamine blocked was used as a background reference in all
experiments. Net resonance response units (RU) were determined by
Table 1
Properties of truncated (Δ) DBP and DBP peptides utilized in SPR binding.
Protein or peptide Symbol Residue # pI Mr Binds to CM5 sensor chip Supports cell binding Blocks cell binding to native DBP
Native DBP DBP 1–458 5.22 51,243 + + +
Domain I DI 1–191 5.37 21,454 + + +
Domain II DII 192–378 4.88 20,817 + − −
Domain III DIII 379–458 4.89 9003 + + +
Δ Domain I (1–175) DI (1–175) 1–175 5.17 19,654 + + +
Δ Domain I (1–125) DI (1–125) 1–125 5.25 13,901 + − −
Domain II+DIII DII+DIII 192–458 5.00 29,778 + + +
Domain II+Δ DIII DII+DIII (379–402) 192–402 4.75 23,590 + + +
Domain II+Δ DIII DII+DIII (379–430) 192–430 5.31 26,720 + + +
Domain I peptide 1 DIp1 130–152 4.66 2875 + − −
Domain I peptide 2 DIp2 150–172 8.77 2479 + + +
Domain III peptide 1 DIIIp1 378–390 4.46 1494 − N.D. −alone
+DIIIp2
Domain III peptide 2 DIIIp2 392–412 8.50 2505 − N.D. −alone
+DIIIp1
Domain III peptide 3 DIIIp3 402–416 9.85 1800 − N.D. −
Domain III peptide 4 DIIIp4 414–434 8.63 2300 − N.D. −
Domain III peptide 5 DIIIp5 438–446 5.50 906 − N.D. −
Domain III peptide 6 DIIIp6 447–458 3.66 1463 − N.D. −
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version 4.1. Each ﬁgure in the Section 3 shows a representative
sensorgram of response units versus time, however, all experiments
were repeated (minimum n≥3) to verify results.3. Results
3.1. Measurement of cell binding to DBP by SPR
The experimental approach to determine the cell binding region
(s) in DBP essentially was the same as previously utilized to identify
the C5a chemotactic cofactor sequence [10]. Truncated forms of DBP
were expressed in E. coli as GST fusion proteins, puriﬁed, and then
utilized to determine if a particular truncated form could block cell
binding to full-length native DBP in Biacore SPR. Overlapping peptides
were synthesized once a region had been narrowed to about 50 amino
acids. As a point of reference, Fig. 1 shows a schematic representation
of the domain structure of DBP with the known functional regions
highlighted. Fig. 2A demonstrates that native DBP was successfully
coupled to a Biacore CM5 sensor chip as detected by the molecular
interaction between immobilized DBP and soluble anti-DBP. Fig. 2B
shows the dose dependent interaction between U937 cells and
immobilized DBP. Cell concentrations below 105/ml showed little
increase in response units (RU), while cell concentrations higher than
2×106/ml had an elevated basal RU after dissociation, making the
sensor chip unsuitable for repeated usage. The cells used in this study
were U937 cells stably transfected with the C5a receptor (U937-C5aR
cells). Nevertheless, the kinetics of DBP binding between U937-C5aR,
U937 cells transfected with an empty plasmid vector or wild-type
U937 cells were identical (data not shown), further supporting ourFig. 1. Schematic representation of the DBP domain structure. The 458 amino acid
sequence of human DBP with the three structural domains and known functional
regions are indicated. Domain I: amino acids 1–191; domain II: 192–378; domain III:
379–458; vitamin D binding: 35–49; C5a chemotactic cofactor: 130–149; G-actin
binding: 373–403. The domain and functional regions are drawn approximately to
scale.previous observation that DBP does not interact with the cell surface
C5a receptor [33]. For optimal results all subsequent experiments
used 106 cells/ml interacting for 3 to 5 min at a ﬂow rate of 10 µl/min.
The increase in RU when cells are injected into the ﬂow chamber was
not due to nonspeciﬁc protein interactions because U937 cells did not
interact with control chips containing either immobilized human β2-
microglobulin or BSA (data not shown).Fig. 2. Initial characterization of DBP–cell binding by SPR. Puriﬁed human DBP was
covalently coupled to a CM5 sensor chip. Panel A: detection of immobilized DBP with
soluble anti-DBP. Panel B: overlay plot of sensorgrams when different U937 cell
concentrations were injected into the ﬂow cell.
Fig. 4. Cell binding to immobilized DBP domains. Puriﬁed recombinant DBP domains
expressed in E. coliwere individually coupled to separate CM5 sensor chips as described
in Section 2. Panel A: detection of immobilized DBP domains with soluble anti-DBP.
Panel B: overlay plot of response curves obtained from the original sensorgrams
examining U937 cell binding to the indicated DBP domain.
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truncated proteins
The capacity of soluble DBP to block subsequent cell interactions
with immobilized DBP was determined next. Fig. 3 demonstrates that
soluble native DBP added to U937 cells, prior to injection into the
Biacore ﬂow chamber, almost completely eliminated cell binding to
immobilized DBP. Conversely, cells pretreated with puriﬁed human
serum albumin were indistinguishable from control (buffer-treated)
cells (data not shown), conﬁrming the speciﬁcity of the DBP–cell
interaction by SPR as we have previously reported using radio-
iodinated ligands [34]. Since full-length native DBP could effectively
block cell binding to immobilized DBP, the effect of pretreating cells
with individual recombinant expressed DBP domains was determined
next. Fig. 3 shows that pretreating cells with puriﬁed domain II did not
alter subsequent cell interaction with DBP whereas domains I and III
could block binding by approximately 50 and 70% respectively. To
investigate if U937 cells can bind directly to puriﬁed DBP domains,
each domain was individually coupled to a separate CM5 sensor chip.
Fig. 4A demonstrates that each domain was successfully coupled to
the sensor chip as detected by the increase in RU with soluble anti-
DBP. Fig. 4B conﬁrms that U937 cells do not bind to domain II but
interact with both immobilized domain III and domain I. A truncated
version of domain I containing amino acids 1–125 (as compared to
full-length domain I at 1–191) also was not able to support cell
binding whereas a 1–175 truncation showed binding identical to full-
length domain I (Fig. 4B). These results indicate that the cell binding
regions in DBP are located in the C-terminal part of domain I (126–
175) and in domain III (379–458).
3.3. Identiﬁcation of a peptide cell localization sequence in DBP domain I
The amino acid sequences responsible for mediating cell binding in
domain I were investigated next using synthetic peptides. U937 cells
were pretreated with either domain I peptide 1 (DIp1), amino acids
130–152, or domain I peptide 2 (DIp2), amino acids 150–172, and the
binding to native DBP was subsequently evaluated. Fig. 5A shows that
DIp2 (150–172) could block cell binding to DBP by about 50%whereas
DIp1 (130–152) was unable to prevent cells from interacting with
immobilized DBP. Direct cell binding to immobilized peptides was
determined after coupling each peptide to a separate sensor chip.
Coupling of the peptides to the CM5 sensor chips was veriﬁed using
anti-DBP (data not shown). Fig. 5B conﬁrms that only the DIp2
sequence (150–172) can support cell binding. Further analysis to
identify the minimal amino acid sequence that supports cells binding,
using three overlapping peptides that span the DIp2 sequence, was
not successful (data not shown). These results indicate that the cellFig. 3. Effect of soluble DBP or DBP domains on cell binding to immobilized DBP. U937
cells (106/ml) in HBSS were pretreated with either buffer (control) or 0.2 µM of native
DBP or the indicated DBP domain for 15 min at 22 °C. Data is presented as an overlay
plot of response curves obtained from the original sensorgrams.binding region in domain I is located in the peptide 2 (DIp2) sequence
residues 150–172 (NYGQAPLSLLVSYTKSYLSMVGS).
3.4. Domain III cell binding sequence overlaps with the actin binding
region in DBP
The cell binding region in domain III was investigated using a
series of six peptides that spanned the entire 80 amino acids of the
domain (Table 1). However, we were unable to link these peptides to
the CM5 sensor chip probably due to their small size and/or cationic
pI's (Table 1). Therefore, we employed an alternative strategy utilizing
recombinant expressed DBP with truncated versions of domain III
attached to domain II. Domain II has superior immobilization to a CM5
sensor chip as detected by anti-DBP (Fig. 4A) but this domain does not
support cell binding (Figs. 3 and 4B). Therefore, domain II serves as an
excellent scaffold to evaluate cell binding in truncated versions of
domain III. Four recombinant expressed DBPs were generated as GST
fusion proteins in E. coli, domain II alone (192–378), full-length
domains II and III (192–458), domain II plus truncated domain III
(379–430), and domain II plus a greater truncation of domain III
(379–402). All four proteins were individually immobilized to a CM5
sensor chip as evidenced by a robust increase in response units when
the ﬂow cell was injected with anti-DBP (data not shown). As noted
previously (Figs. 3 and 4B) domain II alone did not support cell
binding (Fig. 6A). However, Fig. 6A demonstrates that all three forms
of domain III support cell binding to the same extent, indicating that
the binding sequence is located in the N-terminal part of the domain
(379–402). Finally, this portion of domain III was analyzed further
Fig. 5. Cell binding capacity of domain I DBP peptides. Panel A: U937 cells (106/ml) in
HBSS were pretreated with either buffer (control), 0.2 µM of native DBP, 0.2 µM DIp1
(amino acids 130–152) or 0.2 µM DIp2 (amino acids 150–172) for 15 min at 22 °C. Cells
were then injected into the ﬂow cell to interact with immobilized DBP. Data is
presented as an overlay plot of response curves obtained from the original sensorgrams.
Panel B: puriﬁed domain I peptides (DIp1 and DIp2) were individually coupled to
separate CM5 sensor chips as described in Section 2. Data is shown as an overlay plot of
sensorgrams examining U937 cell binding to the indicated domain I DBP peptides.
Fig. 6. Cell binding capacity of DBP domain III sequences. Panel A: overlay plot of
response curves obtained from the original sensorgrams examining U937 cell binding
to the indicated DBP domain. Panel B: U937 cells (106/ml) in HBSS were pretreated
with either buffer (control), 0.2 µM DIIIp1 (amino acids 378–390), 0.2 µM DIIIp2
(amino acids 392–412) or 0.2 µM of both peptides (DIIIp1+2) for 15 min at 22 °C. Cells
were then injected into the ﬂow cell to interact with immobilized DII+ΔDIII (192–
402). Data is presented as an overlay plot of response curves obtained from the original
sensorgrams.
Fig. 7. Schematic representation of the DBP domain structure with proposed cell
binding regions. The 458 amino acid sequence of human DBP with the three structural
domains and known functional regions indicated. Domain I: amino acids 1–191;
domain II: 192–378; domain III: 379–458; vitamin D binding: 35–49; C5a chemotactic
cofactor: 130–149; cell binding #1 (cb1): 150–172; G-actin binding: 373–403; cell
binding #2 (cb2): 379–402. The domain and functional regions are drawn approx-
imately to scale.
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DIIIp2 (392–412). Fig. 6B shows that when cells are pretreated with
either peptide alone there is minimal (b10%) alteration of cell binding
to immobilized domain II plus truncated domain III (379–402). In
contrast, a combination of both peptides reduced subsequent cell
binding by approximately 50% (Fig. 6B), indicating that the domain III
cell binding region is localized to a sequence that spans DIIIp1 and
DIIIp2. This sequence (379–402) largely overlaps with the actin
binding sequence (373–403).
4. Discussion
This paper provides the ﬁrst evidence that human DBP contains
distinct cell targeting sequences that may be required for its multiple
functions. Results reveal two distinct cell binding sequences, one in
the N-terminal domain adjacent to the C5a chemotactic cofactor
region, and the other in the C-terminal domain overlapping with the
G-actin binding sequence (Fig. 7). Furthermore, analysis of the three-
dimensional structure of DBP shows that the location of these
sequences perhaps could allow DBP to function as an adaptor protein
and bridge two distinct cell surface molecules. We propose that the
cell binding sequences be named cb1 (for cell binding #1) for the N-
terminal sequence and cb2 for the C-terminal sequence.
DBP possesses at least four distinct and apparently unrelated
functions: transport protein for vitamin D sterols, extracellular
scavenger for G-actin released at sites of tissue injury, a cofactorthat signiﬁcantly enhances the chemotactic activity of C5a, and a
macrophage and osteoclast activating factor [1,2]. All of these
functions require that DBP interact with the plasma membrane of
its target cell. Indeed, numerous reports have demonstrated that DBP
is associated with the plasma membrane of many different cell types
[11–22], however, very little is known about this process. DBP
interactions with the plasma membrane probably evolved in order to
deliver vitamin D sterols to cells, whereas the other functions may be
cell-speciﬁc adaptations using variations of the basic vitamin D
delivery mechanism. Recently, our lab has begun to deﬁne the cell
surface interactions required for DBP to function as a chemotactic
cofactor for C5a. These reports demonstrate that several molecules are
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dependent) but not to puriﬁed C5a (DBP-independent) [27,30,35]
and suggest that a sequential multi-ligand assembly of a binding site
may be necessary for DBP to mediate this function. However,
detecting cell surface DBP ligands, that may interact only transiently
and with low avidity, is an exceedingly difﬁcult challenge. Thus, we
investigated the converse approach of identifying cell binding regions
in DBP utilizing Biacore SPR to measure the relative binding of U937
cells to immobilized DBP. This technique is superior to employing DBP
covalently coupled to either 125I [24] or Alexaﬂuor-488 [27] because it
evaluates binding in real time. In addition, controls and experimental
samples can be analyzed simultaneously because of the four channel
parallel arrangement of Biacore sensor chips. Consequently, this assay
is considerably more sensitive and the results more reproducible than
previously used techniques [24,27].
The location of the cell binding regions in DBP may hint at their
functional importance. The N-terminal cell binding region (residues
150–172) is immediately adjacent to the C5a chemotactic cofactor
sequence (residues 130–149) and may be needed to localize this
sequence to its cell surface target (Fig. 7). Previously, we have shown
that the C5a chemotactic cofactor sequence peptide can effectively
block full-length DBP from enhancing chemotaxis to C5a [10].
However, the peptide by itself is unable to augment chemotaxis to
C5a perhaps because it requires the adjacent cell surface localization
sequence (residues 150–172). The cell binding sequences may be
required for cell delivery of vitamin D sterols. Saturation of DBP with
vitamin D (either the 25-hydroxy or 1,25-dihydroxy forms) does not
appear to interfere with binding to neutrophils or the myeloid cell
lines HL-60 and U937 [30]. Active vitamin D (1,25 dihydroxy vitamin
D) mediates cellular effects via the vitamin D receptor (VDR), a well
characterized nuclear receptor [36], but also has been shown to
trigger rapid signaling events after binding to the plasma membrane
[36]. This rapid cell surface effect of vitamin D is thought to be
mediated via a protein known as 1,25-D membrane associated rapid
response steroid (MARRS) receptor, also known as ERp57, GRp58 or
ERp60 [37,38]. It is interesting to speculate that DBP also may interact
with the cell surfaceMARRS receptor for delivery of vitamin D. Indeed,
we have reported that active vitamin D (but not the inactive 25-
hydroxy form), when bound to DBP, completely eliminates the C5a
chemotactic cofactor function, an effect that is dependent upon cell
surface alkaline phosphatase (AP) activity [30]. Furthermore, studies
have shown that both cell surface AP [39] and perhaps the MARRS
receptor [40] interact with annexin A2, a molecule that we previously
demonstrated to bind DBP and is required for C5a chemotactic
cofactor activity [27]. Thus, it is conceivable that cell localization
sequences in DBP target the protein to a cell surface protein complex
for delivery of vitamin D sterols.
The other major binding function of DBP is to bind and remove G-
actin from extracellular ﬂuids. DBP–actin complexes have been
detected in the blood of individuals with a variety of conditions
including pregnancy, adult respiratory distress syndrome, sepsis,
bacterial pneumonia, hepatitis, acetaminophen overdose, and multi-
ple trauma cases [1,2]. These complexes are rapidly cleared from the
circulation primarily by the liver [1,2]. Several animal studies (using
rats and rabbits) have demonstrated that DBP–actin complexes are
removed from the blood 5–6 times faster than DBP alone [41–43].
Thus, DBP–actin complexesmay be thought of as a damage-associated
molecular pattern (DAMP), similar to other intracellular molecules
released from necrotic cells such as HMGB-1, and the combination of
cell binding sequences in DBP and actin target the complex to hepatic
scavenger receptors for removal. It is interesting to note that the cell
binding region in the C-terminal domain (residues 379–402) overlaps
with much of the actin binding site (residues 373–403). However, a
previous study from our lab has shown that there is no difference in
cell (neutrophil) binding between DBP alone and DBP–actin com-
plexes, and actin bound to DBP does not alter the C5a chemotacticcofactor function [30]. The deduced linear sequences of both the actin
and cell binding regions are rather large, but the precise amino acid
sequences required for these functions actually may be considerably
smaller and possibly do not overlap. Another possibility is that DBP
may bind actin on the cell surface. The initial binding of DBP to cells is
relatively weak but once it has reached a steady-state plateau
between binding and shedding (30 min at 37 °C) DBP is bound tightly
to the detergent insoluble fraction of the plasma membrane and can
only be dissociated by harsh conditions (1% SDS or 0.1 M carbonate,
pH 11) [24,34]. This would suggest that DBP binds tightly to at least
one of its ligands, and DBP is known to bind G-actin with high afﬁnity
(10−9 M). Actin is the most prevalent intracellular protein, however,
several investigators have reported actin on the extracellular face of
the plasma membrane in lymphocytes and endothelial cells
[11,13,44–46]. Thus, it is conceivable that the tight DBP–membrane
binding is due to the interaction of DBP with cell surface actin. Indeed,
we have observed DBP bound to actin on the plasma membrane of
both neutrophils and the myeloid cell line U937 (L.A. McVoy and R.R.
Kew, manuscript in preparation). The reason that actin is expressed
on the extracellular face of the plasma membrane is not clear but may
reﬂect either cell activation or a pre-apoptotic state.
The signiﬁcance of DBP–cell surface interactions in the functions of
this protein has not been appreciated fully. This study may help to
facilitate future investigations designed to address these questions.
The results reported herein clearly demonstrate that there are only
two cell binding regions in DBP. However, the major caveat with this
study is that the two cell localization sequences have been deﬁned for
leukocytes of myeloid origin and DBP may possess additional binding
regions for other cell types. For example, megalin and cubulin have
been shown to bind DBP [25,26], but these multi-ligand receptors are
expressed largely on epithelial cells, therefore, it is not known if these
cell types utilize the same cb1 and cb2 sequences to bind DBP.
Currently, our lab is expressing recombinant DBPwith deletions in the
cb1, cb2 or both sequences and will use these proteins to screen the
cell binding capacity of a variety of cell types. In summary, human DBP
contains two cell surface localization sequences that may permit the
protein to function as an adapter molecule and bridge two distinct
molecules.
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